Redeye briefly comments on the positive news that Saniona has outlicensed SAN711 to Acadia in neurol...
Educational day with presentations from core holdings DP Patterning: small initial investment, large...
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.
De diskussioner som Eastnine bekräftade i början av november har idag mynnat ut i ett jätteförvärv a...
Vaxxa är ett e-handelsbolag som driver en digital auktionstjänst, där bolaget syftar till att erbjud...
Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
Redeye returns following Kancera’s strategic shift to focus on cardiovascular diseases and its Q3 re...
Redeye provides a research update following the Pharmanovia’s decision to discontinue the partnershi...
ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.
Analyst Group har med Titania ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Redeye update its projections and valuation after Beyond Frames Q3 result.
Redeye briefly comments on Arise’s press release from earlier this week related to the settlement ag...
Q3 weaker, but entering Q4 with better momentum EBIT estimates cut by 3% on '25e-'26e Share is tradi...
Systemair bedöms vända tillbaka till positiv organisk tillväxt i verksamhetsårets andra kvartal.
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK36.
